MX2022012578A - N-cianopirrolidinas con actividad como inhibidores de usp30. - Google Patents
N-cianopirrolidinas con actividad como inhibidores de usp30.Info
- Publication number
- MX2022012578A MX2022012578A MX2022012578A MX2022012578A MX2022012578A MX 2022012578 A MX2022012578 A MX 2022012578A MX 2022012578 A MX2022012578 A MX 2022012578A MX 2022012578 A MX2022012578 A MX 2022012578A MX 2022012578 A MX2022012578 A MX 2022012578A
- Authority
- MX
- Mexico
- Prior art keywords
- cyanopyrrolidines
- activity
- inhibitors
- usp30
- usp30 inhibitors
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title abstract 2
- 101150099494 Usp30 gene Proteins 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101000748132 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 30 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con una clase de N-cianopirrolidinas con actividad como inhibidores de la enzima desubiquitilante USP30, que tiene utilidad en una variedad de áreas terapéuticas, incluyendo condiciones que involucran disfunción mitocondrial, cáncer y fibrosis: (ver Fórmulas).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005250.2A GB202005250D0 (en) | 2020-04-08 | 2020-04-08 | Novel compounds |
| GBGB2016607.0A GB202016607D0 (en) | 2020-10-20 | 2020-10-20 | Novel Compounds |
| PCT/EP2021/059032 WO2021204856A1 (en) | 2020-04-08 | 2021-04-07 | N-cyanopyrrolidines with activity as usp30 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012578A true MX2022012578A (es) | 2022-11-07 |
Family
ID=75441909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012578A MX2022012578A (es) | 2020-04-08 | 2021-04-07 | N-cianopirrolidinas con actividad como inhibidores de usp30. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230119013A1 (es) |
| EP (1) | EP4132925A1 (es) |
| JP (1) | JP2023520727A (es) |
| KR (1) | KR20230006487A (es) |
| CN (1) | CN115461340A (es) |
| AU (1) | AU2021253617A1 (es) |
| BR (1) | BR112022020058A2 (es) |
| CA (1) | CA3171349A1 (es) |
| CO (1) | CO2022014134A2 (es) |
| IL (1) | IL296998A (es) |
| MX (1) | MX2022012578A (es) |
| WO (1) | WO2021204856A1 (es) |
| ZA (1) | ZA202212137B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| EP4441044A1 (en) | 2021-12-01 | 2024-10-09 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| CN117887844B (zh) * | 2023-12-28 | 2024-08-23 | 中山大学附属第一医院 | Usp20在肝癌放疗增敏中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| AU2001256981A1 (en) | 2000-04-06 | 2001-10-23 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| CA2689989A1 (en) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| UY31299A1 (es) | 2007-08-20 | 2009-03-31 | Nuevos inhibidores de catepsina y su uso | |
| CL2009000914A1 (es) | 2008-04-18 | 2010-04-16 | Glaxo Group Ltd | Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica. |
| AR071480A1 (es) | 2008-04-18 | 2010-06-23 | Glaxo Group Ltd | Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd ) |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| WO2015017502A1 (en) | 2013-07-31 | 2015-02-05 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| WO2015183987A1 (en) | 2014-05-27 | 2015-12-03 | Pharmakea, Inc. | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CN107484415B (zh) | 2015-03-30 | 2021-01-29 | 特殊治疗有限公司 | 作为usp30抑制剂的1-氰基吡咯烷化合物 |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) * | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| CN109790112B (zh) | 2016-09-27 | 2022-08-26 | 特殊治疗有限公司 | 具有作为usp30抑制剂活性的氰基吡咯烷衍生物 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| US11247987B2 (en) * | 2017-10-06 | 2022-02-15 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| JP7434285B2 (ja) | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
| MX2021002981A (es) | 2018-10-05 | 2021-05-14 | Forma Therapeutics Inc | Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30). |
| GB201905371D0 (en) * | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
-
2021
- 2021-04-07 BR BR112022020058A patent/BR112022020058A2/pt unknown
- 2021-04-07 KR KR1020227038744A patent/KR20230006487A/ko not_active Withdrawn
- 2021-04-07 EP EP21717825.0A patent/EP4132925A1/en not_active Withdrawn
- 2021-04-07 CN CN202180023434.1A patent/CN115461340A/zh active Pending
- 2021-04-07 CA CA3171349A patent/CA3171349A1/en active Pending
- 2021-04-07 WO PCT/EP2021/059032 patent/WO2021204856A1/en not_active Ceased
- 2021-04-07 US US17/914,414 patent/US20230119013A1/en not_active Abandoned
- 2021-04-07 MX MX2022012578A patent/MX2022012578A/es unknown
- 2021-04-07 IL IL296998A patent/IL296998A/en unknown
- 2021-04-07 JP JP2022561565A patent/JP2023520727A/ja active Pending
- 2021-04-07 AU AU2021253617A patent/AU2021253617A1/en not_active Abandoned
-
2022
- 2022-09-30 CO CONC2022/0014134A patent/CO2022014134A2/es unknown
- 2022-11-07 ZA ZA2022/12137A patent/ZA202212137B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202212137B (en) | 2024-07-31 |
| EP4132925A1 (en) | 2023-02-15 |
| JP2023520727A (ja) | 2023-05-18 |
| KR20230006487A (ko) | 2023-01-10 |
| WO2021204856A1 (en) | 2021-10-14 |
| CA3171349A1 (en) | 2021-10-14 |
| BR112022020058A2 (pt) | 2022-11-22 |
| CO2022014134A2 (es) | 2022-10-31 |
| IL296998A (en) | 2022-12-01 |
| AU2021253617A1 (en) | 2022-12-01 |
| US20230119013A1 (en) | 2023-04-20 |
| CN115461340A (zh) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202203775B (en) | Substituted cyanopyrrolidines with activity as usp30 inhibitors | |
| ZA202212137B (en) | N-cyanopyrrolidines with activity as usp30 inhibitors | |
| MX2023000998A (es) | Composiciones genomodificadas dirigidas a los musculos. | |
| ZA202213866B (en) | N-cyanopyrrolidines with activity as usp30 inhibitors | |
| PH12023550161A1 (en) | Pharmaceutical composition and use thereof | |
| CO2022017233A2 (es) | 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis | |
| PH12022500017A1 (en) | PI3K-a INHIBITORS AND METHODS OF USE THEREOF | |
| MX2016006489A (es) | Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso. | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| MY167691A (en) | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid | |
| PH12021552205A1 (en) | Combinations of rad51 and parp inhibitors | |
| PH12020551555A1 (en) | Calpain modulators and therapeutic uses thereof | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
| ZA202308327B (en) | Methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use | |
| MX2022014429A (es) | N-cianopirrolidinas con actividad como inhibidores de usp30. | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| MX2023002416A (es) | Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina. | |
| PH12022553030A1 (en) | Pharmaceutical formulations of abiraterone acetate and niraparib | |
| WO2020222241A8 (en) | Compositions comprising the propeptide of lysyl oxidase and uses thereof | |
| MX2022014239A (es) | Nuevos agonistas de il10 y metodos para su uso. | |
| WO2023019100A3 (en) | Novel therapeutic methods of using peptidoglycan muropeptides to promote atp synthase activity and mitochondrial homeostasis and development | |
| WO2023056365A3 (en) | Irhom2 inhibitors and uses thereof | |
| ZA202403575B (en) | Method for promoting cell endocytosis of vegetable albumin, and application thereof | |
| PL414890A1 (pl) | Środek aktywujący |